利伐沙班单药与低分子肝素序贯利伐沙班治疗高龄老年静脉血栓栓塞症的临床疗效OA
Efficacy of Rivaroxaban Monotherapy Versus Sequential Use of Low-molecular-weight Heparin Followed by Rivaroxaban in the Treatment of Venous Thromboembolism in Elderly Patients
目的 探讨单用利伐沙班与低分子肝素序贯利伐沙班治疗高龄老年静脉血栓栓塞症(VTE)的临床疗效.方法 选取2021 年1 月至2024 年12 月昆明市第二人民医院收治的80 岁以上老年VTE患者160 例,采用随机数字表法分为试验组与对照组,每组 80 例.试验组予以利伐沙班单药治疗,对照组采用低分子肝素序贯利伐沙班治疗,两组均持续治疗 12 个月.比较两组患者治疗效果、治疗前后肝肾功能及凝血指标,不良反应发生情况.结果 两组治疗12 个月内新发或再发静脉血栓、肺栓塞、心脑血管事件、死亡、血栓变小或消失发生率比较,差异无统计学意义(P>0.05).治疗 1 个月、3 个月、6 个月、12个月后两组D-二聚体(D-D)均降低,但对照组降低幅度更明显,差异有统计学意义(P<0.05);治疗1 个月、3 个月后试验组活化部分凝血活酶时间(APTT)低于对照组,差异有统计学意义(P<0.05);两组治疗前后血小板计数(PLT)、血红蛋白(Hb)、凝血酶原时间(PT)、国际标准化比值(INR)、纤维蛋白原(FIB)、谷丙转氨酶(GPT)及谷草转氨酶(GOT)及血肌酐(SCr)比较差异无统计学意义(P>0.05).治疗期间试验组不良反应发生率为 71.25%,与对照组的 73.75%比较,差异无统计学意义(P>0.05).出血不良反应发生率试验组为 15.00%,对照组为 25.00%,其中消化道出血不良反应发生率试验组为5.00%,对照组为10.00%.两组不良反应发生率较高的主要表现为大便潜血阳性,其次为消化道出血、血尿等.结论 利伐沙班单药治疗与低分子肝素序贯利伐沙班治疗高龄老年VTE临床疗效相当,利伐沙班单药治疗降低APTT更显著,低分子肝素序贯利伐沙班降低D-D水平更显著,均能有效改善患者凝血功能.但利伐沙班具有更高的治疗依从性,出血相关不良事件发生率更低,安全性优势更为显著.
Objective To explore the clinical efficacy of using rivaroxaban alone versus sequential use of low-molecular-weight heparin followed by rivaroxaban in the treatment of venous thromboembolism(VTE)in elderly patients.Methods A total of 160 elderly VTE patients aged over 80 years old who were admitted to Kunming Second People's Hospital from January 2021 to December 2024 were selected.They were randomly divided into the experimental group and the control group,with 80 cases in each group.The experimental group was treated with rivaroxaban alone,while the control group was treated with low molecular weight heparin followed by rivaroxaban.Both groups received continuous treatment for 12 months.The therapeutic effects,liver and kidney functions,and coagulation indicators of the two groups before and after treatment,as well as the occurrence of adverse reactions were compared.Results There was no statistically significant difference in the incidence of new or recurrent venous thrombosis,pulmonary embolism,cardiovascular and cerebrovascular events,death,and reduction or disappearance of thrombus between the two groups within 12 months of treatment(P>0.05).After 1 month,3 months,6 months,and 12 months of treatment,the D-dimer(D-D)levels in both groups decreased,but the decrease in the control group was more significant,with a statistically significant difference(P<0.05);after 1 month and 3 months of treatment,the activated partial thromboplastin time(APTT)in the experimental group was lower than that in the control group,with a statistically significant difference(P<0.05);there was no statistically significant difference in platelet count(PLT),hemoglobin(Hb),prothrombin time(PT),international normalized ratio(INR),fibrinogen(FIB),glutamic-pyruvic transaminase(GPT),glutamic-oxaloacetic transaminase(GOT),and serum creatinine(SCr)between the two groups before and after treatment(P>0.05).During the treatment period,the incidence of adverse reactions in the experimental group was 71.25%,compared with 73.75%in the control group,with no statistically significant difference(P>0.05).The incidence of adverse reactions in the experimental group was 15.00%,and that in the control group was 25.00%.Among them,the incidence of gastrointestinal bleeding adverse reactions was 5.00%in the experimental group and 10.00%in the control group.The main adverse reactions with higher incidence in both groups were positive fecal occult blood,followed by gastrointestinal bleeding,hematuria,etc.Conclusion The clinical efficacy of rivaroxaban monotherapy is comparable to that of sequential low-molecular-weight heparin followed by rivaroxaban in the treatment of VTE in elderly patients.Rivaroxaban monotherapy significantly reduced APTT more effectively,while the sequential use of low molecular weight heparin followed by rivaroxaban significantly reduced D-D levels.Both could effectively improve the coagulation function of patients.However,rivaroxaban had higher treatment compliance,a lower incidence of bleeding-related adverse events,and a more significant safety advantage.
张琳;李海峰;杨晓佳;饶嫱;徐铭蔚;董莎莎
昆明市第二人民医院药学部,昆明 650021昆明市第二人民医院药学部,昆明 650021昆明市第二人民医院药学部,昆明 650021昆明市第二人民医院药学部,昆明 650021昆明市第二人民医院呼吸与危重症医学科,昆明 650021昆明市第二人民医院药学部,昆明 650021
医药卫生
利伐沙班低分子肝素高龄老年人静脉血栓栓塞症
RivaroxabanLow-molecular-weight heparinElderlyVenous thromboembolism
《中国药物经济学》 2026 (6)
39-44,6
昆明市卫生科技项目(2023-13-01-016,2023-03-02-014)
评论